Bolt Biotherapeutics Q2 cash $310.9M; R&D spend doubles; Genmab collaboration on track

Bolt Biotherapeutics, Inc.

Cash, cash equivalents, and marketable securities of $310.9M as of June 30, 2021, expected to fund operations through end of 2023.
R&D expenses $19.7M vs $9.2M YoY; G&A expenses $4.1M vs $2.0M YoY; loss from operations $23.8M vs $11.1M YoY.
Lead program BDC-1001 Phase 1/2 data update expected in 2H 2021; Phase 2 monotherapy and combo dose-escalation to initiate in 2H 2021.
Announced R&D collaboration with Genmab for bispecific ISACs: $10M upfront + $15M equity investment; Genmab fully funds three programs through initial proof-of-concept.
Expanded leadership: added VPs in Clinical Development, Early Development, Biometrics, Program Management, HR, and Communications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.